Compare Bristol-Myers Squibb Co (BMY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs TORM plc — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while TORM plc trades at $29.05 (market cap $2.93B). The key difference: Bristol-Myers Squibb Co is far larger — about 44.3× TORM plc's market cap, and TORM plc pays the higher dividend (9.77%). Which is the better fit depends on your goals.
| BMY | TRMD | |
|---|---|---|
Market Cap | $129.94B | $2.93B |
Sector | Health | Technology |
52-Week High | $65.89 | $34.87 |
52-Week Low | $42.60 | $18.77 |
Enterprise Value | $163.92B | $3.82B |
Dividend Yield | 3.96% | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
TRMD trades at $28.97, down 0.75% today, with technical indicators showing bearish momentum despite oversold RSI conditions. The company maintains strong fundamentals with a P/E of 8.4, net margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, supported by strong tanker market conditions and a $0.70 dividend declaration.
The stock presents a compelling value opportunity with attractive valuation metrics and 100% analyst buy ratings. Key risks include earnings volatility from freight rate fluctuations and negative net cash flow trends. Upside catalysts include potential merger discussions with Hafnia and sustained strong tanker market fundamentals through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
